UBS expects minimal impact in Jazz Pharmaceuticals shares

UBS said the FDA denial of Jazz's 2nd Citizen's Petition was expected and expects minimal pullback in shares. The firm continues to see regulatory hurdles for generic competition for Xyrem and reiterates its Buy rating for Jazz and $64 price target.

View Comments (0)